Association of a dominantly inherited hyperphosphorylated paraprotein target with sporadic and familial multiple myeloma and monoclonal gammopathy of undetermined significance: a case

Association of a dominantly inherited hyperphosphorylated paraprotein target with sporadic and familial multiple myeloma and monoclonal gammopathy of undetermined significance: a case–control study

Published:2009-10 Issue:10 Volume:10 Page:950-956
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Grass Sandra,Preuss Klaus-Dieter,Ahlgrimm Manfred,Fadle Natalie,Regitz Evi,Pfoehler Claudia,Murawski Niels,Pfreundschuh Michael

Publisher

Elsevier BV

Subject

Oncology

Reference46 articles.

1. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study;Landgren;Blood,2009

2. Familial myeloma;Lynch;N Engl J Med,2008

3. Risk of plasma-cell and lymphoproliferative disorders among 14,621 first-degree relatives of 4,458 patients with monoclonal gammopathy of undetermined significance (MGUS) in Sweden;Landgren;Blood,2009

4. Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders;Brown;Blood,2008

5. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States;Landgren;Blood,2006

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Autoantibody mediated Deficiency of IL-36-Receptor antagonist in a subset of patients with Psoriasis and Psoriatic Arthritis;Immunology Letters;2024-09

2. Autoimmune Diseases and Plasma Cells Dyscrasias: Pathogenetic, Molecular and Prognostic Correlations;Diagnostics;2024-05-29

3. SOHO State of the Art Updates and Next Questions: Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma;Clinical Lymphoma Myeloma and Leukemia;2024-03

4. EXABS-121-MM MGUS/SMM: Incidence, Evaluation and Follow-up;Clinical Lymphoma Myeloma and Leukemia;2023-09

5. Autoantibodies neutralizing antiinflammatory mediators in the context of SARS-CoV-2 infection and COVID-19;Autoimmunity, COVID-19, Post-COVID19 Syndrome and COVID-19 Vaccination;2023